Viking Therapeutics
VKTX
168 hedge funds and large institutions have $360M invested in Viking Therapeutics in 2018 Q4 according to their latest regulatory filings, with 51 funds opening new positions, 72 increasing their positions, 37 reducing their positions, and 29 closing their positions.
95% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 37
76% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 29
28% more call options, than puts
Call options by funds: $8.42M | Put options by funds: $6.59M
14% more funds holding
Funds holding: 148 → 168 (+20)
4.4% more ownership
Funds ownership: 61.39% → 65.79% (+4.4%)
52% less capital invested
Capital invested by funds: $753M → $360M (-$394M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fiera Capital (Canada)
Montreal,
Quebec, Canada
|
+$17.5M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$11.6M |
| 3 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$11.1M |
| 4 |
BlackRock
New York
|
+$8.96M |
| 5 |
State Street
Boston,
Massachusetts
|
+$8.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$25.9M |
| 2 |
Janus Henderson Group
London,
|
-$15.5M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$8.74M |
| 4 |
RI
RTW Investments
New York
|
-$8.71M |
| 5 |
DM
Deerfield Management
New York
|
-$8.01M |
VKTX Hedge Fund Activity: Q4 2018 in Review
168 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q4 2018, worth a combined $360M — down 52% from $753M a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new VKTX positions and 29 closed out — a net gain of 22 holders — while 72 added to existing stakes and 37 trimmed.
The largest buyer was Fiera Capital (Canada), opening a new position worth an estimated $17.5M. The largest seller was Fidelity Investments, cutting an estimated $25.9M.
- 168 institutional investors held Viking Therapeutics (VKTX) as of Q4 2018, up from 148 in Q3 2018.
- Funds reported $360M of Viking Therapeutics stock for Q4 2018, down 52% quarter-over-quarter.
- 51 funds opened new Viking Therapeutics positions in Q4 2018 and 29 closed out, a net change of +22 holders.
- The largest Viking Therapeutics buyer in Q4 2018 was Fiera Capital (Canada), an estimated $17.5M added.
- The largest Viking Therapeutics seller in Q4 2018 was Fidelity Investments, an estimated $25.9M sold.
Based on aggregated 13F filings for Q4 2018.